Bacterial infections are a leading cause of death worldwide and the relentless evolution of antimicrobial resistance renders currently available antibiotics ineffective at an increasing pace. Recent studies estimate that by 2050, antibiotic resistance could lead to as many as 10 million mortalities annually and societal costs in excess of 100 trillion USD.

Antibiotic Resistance

Antibiotic resistance is a natural evolutionary phenomenon wherein bacteria prevent an antibiotic from working against an infection. Antibiotics and antimicrobial drugs have been used since the 1930’s to treat patients suffering from infectious diseases. However, due to their prolonged use, infectious organisms develop resistance towards antibiotics. Over the course of several years, improper use and misuse of antibiotics have led to a dramatic increase in the number of antibiotic resistant bacteria. Today, antibiotic resistance is an alarming global problem charged by the spread of bacteria across the world.

The reasons for the development of antibiotic resistance are complex and while most current antibiotics are on the verge of becoming ineffective against resistant strains of bacteria, very few efforts are being taken to develop newer and more effective antibiotics.

Over the past 40 years, only two new antibiotic classes have been brought to patients. Public healthcare systems and drug developers have been relying on analogues of existing antibiotics, but due to rapid emergence of renewed resistance to analogues of already challenged antibiotics, this approach has failed to address the threat from multi-drug resistance. To overcome this threat, new classes of antibiotics are needed.


AntibioTx has identified, characterized, and patent protected a new class of antibiotics. The Tx-class of antibiotics has broad applicability against multi-drug resistant pathogens and infections. Additionally, it is significantly de-risked due to decades of safe use for non-related purposes. AntibioTx has outlined a broader pipeline and has entered the clinic with the lead candidate, ATx201.  

For a recent report on the unpleasant outlook, please see: The AMR Review, Tackling Drug-Resistant Infections Globally: Final report and recommendations

Read more